The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure

Author(s): Vasiliki Tsigkou*, Gerasimos Siasos*, Evanthia Bletsa, Maria-Evi Panoilia, Angeliki Papastavrou, Georgios Kokosias, Evangelos Oikonomou, Nikolaos Papageorgiou, Marina Zaromitidou, Georgios Marinos, Manolis Vavuranakis, Christodoulos Stefanadis, Athanasios G. Papavassiliou, Dimitris Tousoulis

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 27 , 2020

Become EABM
Become Reviewer

Abstract:

Intensive research has shed light on the utilization of novel biomarkers which facilitate the diagnosis and prognosis of patients with different medical problems. One of the most important biomarkers especially in the spectrum of heart failure is soluble ST2 (sST2: soluble Suppression of Tumorigenicity 2), which is involved in inflammation, fibrosis and cardiac stress. In the revised 2017 ACC/AHA/HFSA, “Focused Update Guidelines for the Management of Heart Failure” ST2 was given a class-IIa recommendation for the optimal risk assessment in patients with heart failure. Many studies indicate that not only baseline but also serial measurements of ST2 can accurately predict future cardiovascular events in patients with Acute Coronary Syndromes and heart failure. Therefore, in this review, we are going to discuss the studies about the prognostic significance of ST2 in patients with Acute Coronary Syndromes, acute and chronic heart failure.

Keywords: Acute Coronary Syndromes (ACS), biomarkers, coronary artery disease, heart failure, biomarkers, prognosis.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 27
Year: 2020
Page: [4479 - 4493]
Pages: 15
DOI: 10.2174/0929867326666191016121630
Price: $65

Article Metrics

PDF: 11